CLEVELAND, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX), a leader in the emerging field of regenerative medicine, today announced the termination of its collaboration with Angiotech Pharmaceuticals, Inc. (Angiotech) to co-develop cell therapy in the cardiovascular field. In connection with the mutual termination, Athersys has regained all rights in its MultiStem® cardiovascular program, allowing it greater flexibility in clinical development and the opportunity to pursue new business collaborations within or including this important field.
